GlassScriptPhysician profile
Robert F Gray
NPI 1790757904
$8,370.86
in general payments reported to CMS, 2019-2025
20 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $620 · 2021: $1,171 · 2022: $3,302 · 2023: $650 · 2024: $1,126 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192 · Entertainment: $23.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.57 |
| Entertainment | $23.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $3,676.64 | 2019-2025 | Myday Contact Lens, Paragon Crt, Ortho-K Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,212.74 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $853.89 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $653.65 | 2022-2025 | Infuse, Biotrue One Day |
| Johnson & Johnson Vision Care, INC. | $650.46 | 2019-2023 | Acuvue |
| Alcon Vision LLC | $504.21 | 2019-2025 | Total30, Precision 1, Precision7 |
| Lkc Technologies, INC. | $237.25 | 2024-2025 | |
| Kala Pharmaceuticals, INC. | $148.92 | 2021-2022 | |
| Lumenis, INC | $102.52 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.84 | 2020-2021 | |
| Tarsus Pharmaceuticals, INC. | $39.54 | 2025 | Xdemvy |
| Abbvie INC. | $38.64 | 2022-2025 | |
| Abb Con-Cise Optical Group LLC | $37.43 | 2019 | |
| Allergan, INC. | $37.14 | 2021 | |
| Maculogix, INC. | $31.61 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $23.01 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Dompe US, INC. | $22.33 | 2025 | Oxervate |
| Shire North American Group INC | $20.12 | 2019 | |
| Mallinckrodt Hospital Products INC. | $19.52 | 2023 | Acthar |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.